Diabetes
From the Journals
Artificial pancreas treatment improves glycemic control in T1DM: Meta-analysis
Closed-loop glucose control systems increase the time in normoglycemia for type 1 diabetic patients, but is it enough?
From the Journals
Nitric oxide–generating dressing holds promise for diabetic foot ulcers
Experimental treatment boosts reduction of wound size, researchers say, but one critic wonders about closure rates.
From the Journals
Targeting obesity could slow brain aging in psychosis
"The brains of participants with [first-episode psychosis] appeared on average 2.64 years older than their chronological age."
Daily News Podcast
MDedge Daily News: Which diabetes drug boosts survival best?
And there’s new promise in early-stage lung cancer.
From the Journals
‘Fast food swamps’ linked to type 1 diabetes
Greater concentrations of fast food restaurants in an area have been linked to a higher prevalence of pediatric type 1, but not type 2, diabetes...
From the Journals
VIDEO: Meta-analysis: Mortality, safety data may favor SGLT2 inhibitors in T2DM
GLP-1 agonists were associated with a higher risk of adverse events that led to study withdrawal, compared with SGLT2 inhibitors.
News
FDA approves marketing for retinal imaging device that uses artificial intelligence
Using AI, the IDx-DR identifies the presence of diabetic retinopathy nearly 90% of the time without the need of an eye care specialist.
Daily News Podcast
MDedge Daily News: Diabetes patients ignore a deadly risk
And a three-in-one pill could change hypertension treatment.
Conference Coverage
Cardiovascular risk in type 2 diabetes: Patients are often clueless
A survey showed most patients with type 2 diabetes are unaware of their elevated cardiovascular risk.
Conference Coverage
Diabetes from checkpoint inhibitors probably means lifelong insulin
CHICAGO – In the largest case series to date, almost all patients remained on insulin at a median follow-up of 44 weeks, even after stopping ICIs...
Conference Coverage
Clearer picture emerging of renal impact of SGLT2s
It’s true, it’s true, EMPA-REG shows that SGLT2 inhibitors are renal protective in type 2 diabetes.